Silverback Therapeutics, Inc. (SBTX) Stock Analysis
DELISTED
What happened to Silverback Therapeutics, Inc. (SBTX) stock?
Silverback Therapeutics, Inc. (SBTX) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $550M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Silverback Therapeutics, Inc. (SBTX). Silverback Therapeutics, Inc. is a biopharmaceutical company focused on developing tissue-targeted therapeutics. Their lead product, SBT8230, targets chronic hepatitis B virus infection by activating TLR8 in the liver to elicit an anti-viral immune response.
Last analyzed: Mar 18, 2026Silverback Therapeutics, Inc. (SBTX) Healthcare & Pipeline Overview
More about this archive record
Can I still buy SBTX shares?
No. SBTX stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for SBTX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SBTX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Silverback Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.